The evolving role of gene-based treatment in surgery

Tan, Peng; Chan, Christopher L.; George, Andrew J.T.

doi:10.1002/bjs.5181

Cited by 12 publications

(6 citation statements)

References 139 publications

(138 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to highlighting the role of IDO in graft rejection, these data inform the development of gene therapy techniques to prevent graft rejection. The endothelium is a very promising target for gene transfer in the context of transplantation, not only because of its role in preventing graft rejection but also because of its accessibility to gene transfer vectors (37). The transfer of the gene encoding IDO has been shown to be effective in prolonging the survival of islet (38), lung (39) and corneal (28) allografts in animal models.…”

Section: Discussionmentioning

confidence: 99%

Expression of Indoleamine 2,3-Dioxygenase (IDO) by Endothelial Cells: Implications for the Control of Alloresponses

Beutelspacher

Tan

McClure

et al. 2006

American Journal of Transplantation

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Expression of Indoleamine 2,3-Dioxygenase (IDO) by Endothelial Cells: Implications for the Control of Alloresponses

Beutelspacher

Tan

McClure

et al. 2006

American Journal of Transplantation

View full text Add to dashboard Cite

“…Many of the developments needed to translate neuronal gene transfer into the clinic do not concern the genetic information to be delivered, but rather, the delivery tool itself: the vector [49,[57][58][59][60]. Unfortunately vector development is a significantly under-financed field [61][62][63], as many difficult and time-consuming technological breakthroughs can be perceived by evaluators as "physiologically irrelevant" if such work is not coupled to a disease model and/or carried out by a disease-oriented research group.…”

Section: Vector Developmentmentioning

confidence: 99%

Gene Therapy Approaches to Ataxias

Lim

Diaz-Nido²

2009

CGT

View full text Add to dashboard Cite

Gene therapy has been a clinical possibility since 1989 and the steadily increasing number of clinical trials now includes strategies targeting neurodegenerative conditions such as lysosomal storage disease, multiple sclerosis, Alzheimer's and, Parkinson's disease. In spite of lack of knowledge of the molecular causes of these diseases, results so far in these trials have been promising. Thus there is gaining confidence in the potential to develop effective treatments based on gene transfer for neurological diseases in the near future. Furthermore, the accelerating progress in knowledge of the molecular pathologies of neurogenetic disorders, including rare diseases such as the ataxias, makes them even more amenable to gene therapy. Here we review recent preclinical studies relevant to gene therapy of ataxias and discuss developments needed to bring these strategies into the clinic.

show abstract

“…There is ample evidence supporting the fundamental concept that cancer is a genetic disease [4][5][6][7] and so molecular avenues of research hope to identify future targets to attack this disease [8]. The body of work regarding the molecular basis of colorectal cancer is growing at pace but as yet remains a subject of ongoing debate [9][10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Molecular changes consistent with increased proliferation and invasion are common in rectal cancer

et al. 2011

View full text Add to dashboard Cite

BACKGROUND Survival in rectal cancer remains unchanged despite improved treatment modalities. Molecular biology may hold the key to new strategies. Gene expression abnormalities need identification in tumour specimens to identify targets for therapy. The impact of neoadjuvant therapy on induced gene expression changes needs to be assessed to distinguish the intrinsic tumour-specific changes from those changes that may be induced by neoadjuvant therapy. METHODS Gene expression changes were examined in 21 rectal tumours plus matched normal mucosa and cells exposed to 5-FU and gamma radiation, using DNA membrane arrays. These arrays contained 100 genes in common cancer pathways. The most commonly up-regulated gene, c-FOS, was quantified using real-time PCR. RESULTS c-FOS was the most commonly up-regulated gene, occurring in 7 of 21 samples (33%), all samples having a greater than 2-fold increase. SERPINE-1 was the second most commonly up-regulated gene with 6 of 21 samples showing up-regulation (29%). There was no clear correlation between up-regulation of c-FOS or SERPINE-1 and clinico-pathological data. Neither c-FOS nor SERPINE-1 gene expression was induced by 5-FU treatment or gamma irradiation in vitro, but MUC 18 was up-regulated by 5-FU treatment. This suggests that FOS and SERPINE-1 expression changes are specific to the tumour and will not arise as artefacts of neoadjuvant therapy. CONCLUSION The study suggests that c-FOS and SERPINE-1 may have important but as yet unclear roles in the tumour biology of rectal cancer but probably only represent a small part of the complex molecular biology of rectal cancer.

show abstract

The evolving role of gene-based treatment in surgery

Cited by 12 publications

References 139 publications

Expression of Indoleamine 2,3-Dioxygenase (IDO) by Endothelial Cells: Implications for the Control of Alloresponses

Expression of Indoleamine 2,3-Dioxygenase (IDO) by Endothelial Cells: Implications for the Control of Alloresponses

Gene Therapy Approaches to Ataxias

Molecular changes consistent with increased proliferation and invasion are common in rectal cancer

Contact Info

Product

Resources

About